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ABSTRACT  Glycoprotein  (GP) Ib  was  purified  from  lysates of  human platelets prepared  in  the 
presence or absence of inhibitors of the endogenous calcium-activated neutral protease (CANP) by 
immunoaffinity  chromatography,  employing  the GPlb-specific  murine  monoclonal  antibody,  APt, 
coupled  to  Sepharose CL4B. When  derived  from  lysates prepared in  the  presence of  EDTA or 
leupeptin,  the eluate from the APt-affinity column contained a 240,000-260,000-mol-wt  protein  in 
addition to GPIb. In  SDS  PAGE, this  protein  was  stained by Coomassie Blue R,  but  not by the 
periodic acid-Schiff reagent, and it was not labeled with 12sI in intact platelets by the lactoperoxidase- 
catalyzed method.  When  derived  from  lysates prepared in  the  absence of CANP inhibitors,  the 
eluate contained only GPIb and its proteolytic  derivative, glycocalicin. 
A change in the electrophoretic  mobility of GPIb consistent with its association with the 240,000- 
260,000-mol-wt  protein  was  confirmed  by  crossed immunoelectrophoresis.  By  an  immunoblot 
technique involving transfer of proteins eluted from the APt-affinity column and separated by SDS 
PAGE onto a nitrocellulose membrane, the 240,000-260,000-mol-wt  protein bound polyclonal goat 
antibody raised against rabbit macrophage actin-binding  protein (ABP). 
On the basis of these results, we conclude the GPIb is tightly associated with ABP under conditions 
in which  the endogenous CANP is  inhibited,  and that this apparent transmembrane complex  of 
GPIb-ABP can be isolated in lysates of nonactivated human platelets. 
The murine monoclonal antibody, AP 1, recognizes an epitope 
common to human platelet membrane glycoprotein (GP)  ~  Ib 
and its proteolytic derivative, glycocalicin (9,  1 l,  20).  In a 
rapid whole blood binding assay (l 1), API was shown to react 
with platelets from all normal donors tested and six patients 
with Glanzmann's thrombasthenia, a hereditary disorder of 
platelet cohesion characterized by the absence of GPIIb and 
GPIIIa (13). By the same assay, no reaction was observed with 
platelets from three  patients with the  Bernard-Soulier syn- 
drome  (BSS),  a  hereditary  disorder  of platelet-vessel wall 
adhesion characterized by the absence of platelet GPIb (13). 
Recently, Ruggeri et al.  (20) showed that platelet binding of 
[IESI]von Willebrand factor (vWf) induced by ristocetin was 
completely blocked  by prior  exposure  to  API,  while  that 
induced by ADP +  epinephrine was unaffected. This finding 
t Abbreviations used in this paper.  ABP, actin-binding protein; BSS, 
Bernard-Soulier syndrome;  CANP,  calcium-activated neutral  pro- 
tease; CBR, Coomassie Blue-R; CIE, crossed immunoelectrophoresis; 
GP, glycoprotein; PAS, periodic acid-Schiff reagent; vWf, von Wil- 
lebrand factor. 
supports the hypothesis that GPIb is involved in the ristocetin- 
induced binding of vWf, while the GPIIb-GPIIIa complex, 
but not GPIb, is involved in the expression of thrombin- or 
ADP +  epinephrine-induced platelet receptors for vWf. 
To obtain additional insight into the structure and function 
of  GPIb and its relationship to other membrane and nonmem- 
brane components, we purified the glycoprotein by immu- 
noaffinity chromatography. Since Solum et al. (23) had re- 
ported that GPIb may be associated in complexes that are 
disrupted by the endogenous calcium-activated neutral pro- 
tease (CANP), we analyzed lysates prepared in the presence 
or absence of inhibitors of CANP. As noted in a preliminary 
report (9), this experimental approach confirmed the existence 
of soluble complexes of GPIb and a 240,000-260,000-mol-wt 
platelet  protein.  We  now  report  the  identification  of this 
protein as actin-binding protein (ABP). 
MATERIALS AND  METHODS 
Monoclonal  IgG  was  isolated  from  ascites fluids and labeled with  ~25I as 
previously described (1 1,  17). Crossed immunoelectrophoresis (CIE) was per- 
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intermediate  gel  (8,  11), and  precipitin  arcs  containing  bound monoclonal 
antibody were revealed by autoradiograpby.  Immunoaffinity  chromatography 
using AP 1  coupled to Sepharose CL4B (Pharmacia Fine Chemicals, Piscataway, 
N  J) and assays of the direct binding of [~:~I]AP1 to platelets were performed as 
described (17). SDS PAGE was performed in 3-mm thick, 7  % acrylamide slab 
gels as  described  by  Nurden et  al.  (14). Apparent  molecular  weights were 
calculated by direct comparison to the mobilities of  the following known protein 
standards  (Bio-Rad  Laboratories,  Richmond,  CA): myosin  (200,000);  beta- 
galactosidase  (117,000);  phosphorylase  b  (94,000);  bovine  serum  albumin 
(69,000); and ovalbumin (43,000). 
Immunoblot  Method:  After  SDS  PAGE,  gels were  incubated  in 
0.025 M Tris-HC1, 0.192 M glyeine, 20% (vol/vol) methanol  (pH 8.2) for 30 
rain  at ambient temperatures  and sandwiched against a  nitrocellulose mem- 
brane  (Bio-Rad  Laboratories)  in a  Transblot  apparatus  (Bio-Rad).  Proteins 
were transferred  by  electrophoresis  at  60  V  for  3  h  and  30  min at  4"C. 
Nonreacted  nitrocellulose was then blocked by incubation  for 1 h in 0.01 M 
Tris-HC1, 0.145 M NaCI (pH 7.0) containing  1% gelatin, followed by two 10- 
rain washes in the same buffer containing  0.5% gelatin, 0.5% Triton  X-100 
and 0.01% NAN,. The membrane was then incubated  for 18 h with agitation 
in  50  ml of the  latter  mixture  containing  0.25 ml of goat antiserum  raised 
against rabbit macrophage ABP. This antiserum, a generous gift from John H. 
Hartwig, Ph.D. (Hematology-Oncology Unit, Massachusetts General Hospital, 
Boston) cross-reacts with ABP from human platelets  2. The membrane was then 
washed five times in the same buffer mixture without antiserum,  incubated for 
6 h  in  50  ml  of the  same buffer mixture  containing  affinity-purified, [~2~l]- 
rabbit anti-goat IgG (l0  s cpm/ml [Zymed Labs, Inc., So. San Francisco, CA]), 
and finally washed five times in the same buffer mixture containing 0.2% SDS. 
The membrane was immediately blotted without drying and packaged within 
a plastic bag. For autoradiography,  membranes within plastic bags were sand- 
wiched  between  Kodak  XRP-I  x-ray  film  and  a  Dupont Cronex  Hi  Plus 
Intensifying screen for I to 24 h at ambient temperature in a light-proof Kodak 
x-ray film cassette. 
Additional murine monoclonal  antibodies were used in these studies: anti- 
fibronectin (ATCC CRL 1605) was obtained commercially; anti-vWf (AVW2), 
reactive with  all  multimers,  was produced  in the laboratory  of Dr.  Robert 
Montgomery (21). 
Piatelet cytoskeletons, as a source of semi-purified ABE were prepared as 
described by Rosenburg  et at. (19), except that 0.01 M  HEPES was used in 
place of 0.01 M imidazole-chloride in the "Triton solubdization buffer." This 
modification  was without apparent effect upon the composition  of the cyto- 
skeleton complex subsequently isolated. 
RESULTS 
Steady-state Binding of AP1 to Human Platelets 
On the basis of data derived from eight different healthy 
donors, we found that the number of API  molecules bound 
per platelet at saturation was 34,200  _+ 5,400 (mean _-!-  SD), 
with an average dissociation constant (Kd) of 2. l  _+ 0.4 nM. 
No difference in binding was noted at room temperature in 
the  presence  or  absence  of divalent  cations.  Comparative 
studies with washed platelets derived from whole blood anti- 
coagulated with citrate, EDTA, acid-citrate-dextrose, or hep- 
arin gave equivalent results. 
CIE 
[125I]AP1 was incorporated into the intermediate gel before 
the  start of the  second  dimension  electrophoresis,  and  the 
precipitin  arcs containing  antigens reactive with  AP1  were 
revealed by autoradiography of the dried gels (Fig.  1). When 
platelets were lysed in  the  absence of leupeptin  or EDTA, 
AP1 bound solely to two cross-reactive precipitin arcs known 
from previous studies (6) to contain GPIb and glycocalicin, 
respectively (Fig.  1  B). In lysates from identical platelets pre- 
pared in the presence of 0.4 mM leupeptin (Fig.  1  A), at least 
two additional cathodic precipitin arcs were labeled by ['25I]- 
API, one of which was a  sharp "spike" situated directly over 
2 j.  Hartwig, personal communication. 
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FIGURE  1  ClE.  Identical washed platelet samples were lysed in the 
presence  (A) or absence  (B) of 0.4  mM  leupeptin. Triton X-100 
soluble protein (100 #g) was electrophoresed against a mixture of 
polyspecific rabbit anti-human platelet antibody and ['2Sl]API. Gels 
were stained with CBR, dried, and subjected  to autoradiography. 
The  resultant  autoradiographs were  depicted  below the  corre- 
sponding CBR-stained gel. The position of the precipitin arcs given 
by GPIb and glycocalicin (G) are indicated. Arrowheads in gel A 
indicate the additional cathodic precipitin arcs to which [12Sl]AP1 
also bound. 
the sample well (open arrowhead in Fig.  1A). Essentially the 
same  results  were  obtained  from  lysates  prepared  in  the 
presence of 5 mM EDTA, although the spike precipitin arc 
was not as pronounced as that seen in lysates prepared with 
leupeptin.  Radiolabeled,  monoclonal  antifibronectin  and 
anti-vWf (AVW2) bound to respective precipitin arcs known 
to contain these antigens, but neither bound to the cathodic 
precipitin  arcs  reactive  with  radiolabeled  AP1  (data  not 
shown). 
Immunoaffinity Chromatography 
Purified  API  IgO  was  covalently  coupled  to  cyanogen 
bromide-activated  Sepharose  CL4B.  Triton  X-100  lysates 
derived  from the  same preparation  of washed,  125I-labeled 
platelets,  in  the  absence or presence of 0.4  mM leupeptin, 
were chromatographed on identical AP1-Sepharose columns 
equilibrated  in  buffer containing  leupeptin.  Bound  protein 
was  eluted  by  a  multistep  elution  protocol  (17);  the  final elution buffer contained 0.05 M diethylamine (pH 11.5). Each 
eluate was then analyzed by SDS PAGE. Protein bands were 
visualized  by  staining  with  Commassie  Blue-R  (CBR)  or 
periodic acid-Schiff  reagent (PAS). 
When lysates prepared in the presence of leupeptin were 
analyzed, a  PAS-positive, radiolabeled protein with an elec- 
trophoretic mobility following reduction with 2-mercaptoeth- 
anol  characteristic  of the  larger  subunit,  or  alpha  chain, 
(145,000-mol-wt), of GPIb was eluted only upon addition of 
diethylamine (Fig. 2, solid arrowhead in lanes A-C). A PAS- 
positive band of identical mobility and present in the original 
lysate (Fig.  2,  lane  1)  was  seen  to  be  depleted  from  the 
nonadherent fraction (Fig.  2,  lane 2).  In  addition to GPIb 
alpha,  the diethylamine-eluate contained a  high  molecular 
weight protein (240,000-260,000) that was stained by CBR 
(Fig.  2,  open arrowhead in  lane A), but PAS-negative and 
nonradiolabeled (Fig.  2, lanes B and C). Eluates derived by 
addition of 1 M NaC1 often contained detectable amounts of 
the 240,000-260,000-mol-wt protein, but never contained a 
protein band  equivalent to  GPIb  alpha.  Identical proteins 
were contained in diethylamine-eluates derived from lysates 
prepared in the presence of 5 mM EDTA. 
When lysates prepared in the absence ofleupeptin or EDTA 
were analyzed, diethylamine-eluates were found to contain 
two closely migrating protein bands (with molecular weights 
of 140,000  and  135,000)  that were both PAS-positive and 
radiolabeled (Fig.  2,  arrows in  lane D).  Based  upon  these 
apparent molecular weights, the former protein is likely GPIb; 
the latter, glycocalicin. No trace of the 240,000-260,000-mol- 
wt protein was detected either in diethylamine-eluates or 1 M 
NaCl-eluates derived from lysates prepared in the absence of 
leupeptin or EDTA. 
Immunoblot 
As  shown  in  Fig.  3,  the  platelet lysate used to generate 
purified GPIb (lane A) was directly compared to a cytoskele- 
ton complex preparation enriched in ABP (lane B), and the 
fraction containing the GPIb-high molecular weight protein 
complex eluted from an AP 1-Sepharose affinity column (lane 
C). By this method, the 240-260,000-mol-wt protein that is 
co-purified with GPIb (cf. Fig. 2, lane A) was shown to cross- 
react with antibody specific for ABP. 
Specificity  of AP1 
As shown previously, AP 1 reacts with OPIb and glycocali- 
cin (9,  11, 20). In the present study, it was necessary to show 
that AP1  does not also react with ABP leading to artifactual 
isolation of  ABP along with GPIb. The monoclonal antibody, 
AP 1, is nonreactive in the SDS PAGE immunoblot technique. 
Thus, it became necessary to isolate ABP from GPIb. As it 
has been difficult to prepare an ABP preparation that does 
not contain some contamination of GPIb, we used platelets 
from a patient with the BSS which lack GPIb (13).  A cyto- 
skeletal preparation from BSS platelets contains ABP as dem- 
onstrated  by  immunoblot  technique  with  goat  anti-ABP 
serum.  Reaction of AP1  with the  cytoskeletal preparation 
from BSS  platelets could not be detected using an  ELISA 
technique. The cytoskeletal preparation was adsorbed onto 
Immulon I plates (Dynatech Laboratories, Inc., Alexandria, 
"CA) and reaction with API  assayed using the biotin/avidin 
system for mouse IgG detection (Vector Laboratories, Inc., 
Burlingame, CA). 
FIGURE 2  Immunoaffinity  chromatography.  Lysates from  1251-1a- 
beled platelets  prepared  in the presence  or absence  of leupeptin 
were passed through affinity columns composed of API  coupled 
to Sepharose CL4B.  Protein composition of column fractions was 
determined  by  SDS  PAGE after  addition  of  2-mercaptoethanol. 
Indicated in the figure: the total  platelet lysate  stained  with  PAS 
(lane I); the nonadherent fraction stained with PAS (lane 2); bound 
protein eluted with diethylamine, stained with CBR (lane A) or PAS 
(lane B), or visualized by autoradiography (lanes C and D).  Protein 
in lanes  I, 2, A, B, and C was derived from  platelets  lysed in the 
presence of leup@ptin; protein in lane D was derived from the same 
platelet sample lysed in the absence of leupeptin. The positions of 
selected  platelet proteins (thrombospondin [T], and glycoproteins 
Ib  alpha,  llb  alpha,  llla,  and  IV)  are  indicated  in  lane  I.  Open 
arrowhead in lane A indicates the position of the protein that is co- 
purified with GPIb. The apparent molecular weight of this protein 
is estimated  to be in the range of 240,000-260,000 by extrapolation 
from  the highest molecular weight standard  used  (myosin  [M, = 
200,000]).  Closed arrowheads in lanes A-C indicate the position of 
glycoprotein Ib alpha (M, 145,000). Double arrows in lane D indicate 
the position of glycoprotein Ib alpha (Mr 140,000) and glycocalicin 
(Mr 135,000). dr, Dye front. 
DISCUSSION 
Based upon partial immunologic identity and similarities in 
tryptic peptide maps, there is now little doubt that GPIb and 
glycocalicin are structurally related (1,  15, 22), and that gly- 
cocalicin is derived from GPIb by the action of  an endogenous 
CANP (10, 22, 23, 25). 
Using CIE, Solum et al. (23) demonstrated that cleavage of 
GPIb by CANP can occur within intact platelets stimulated 
with local anesthetics, such as dibucaine, and that the mobility 
of GPIb within the first dimension of CIE gels is impeded in 
lysates prepared under conditions that would inhibit the en- 
dogenous CANP.  Activation  of the  endogenous CANP  in 
intact platelets with the ionophore A23187 in the presence of 
calcium has also been shown to result in the proteolysis of 
GPIb with release of  glycocalicin (10). An additional substrate 
of CANP, ABP, has also been shown to be cleaved concomi- 
tant with platelet activation by thrombin or A23187 (7,  16, 
24). Thus, it has been postulated that proteolysis of selected 
substrates, perhaps GPIb and/or ABP, by CANP may be a 
requisite step in platelet activation. 
The results of our studies confirm and extend the initial 
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lysate prepared in the presence of 5 mM EDTA, (B) isolated platelet 
cytoskeleton complex, and (C) the eluate from an AP1-Sepharose 
column derived from the lysate shown in A, were separated by SDS 
PAGE and transferred  to nitrocellulose. Bound proteins were then 
exposed  to  goat  anti-rabbit  macrophage  ABP  followed  by  [12Sl]- 
rabbit anti-goat IgG. The autoradiograph derived from this immu- 
noblot experiment is depicted in this figure.  The intensely labeled 
band corresponding to ABP is indicated. In A, an additional labeled 
band  is  present  that  co-migrates  with  human  serum  albumin  in 
reduced  (Mr  65,000-67,000)  or  nonreduced  (Mr  45,000-50,000) 
(not shown) SDS PAGE/immunoblot, and thus is probably platelet 
albumin. Human serum albumin also reacts with the anti-ABP serum 
in these immunoblot experiments (data not shown). The position 
of molecular weight markers is indicated to the left of the figure (Mr 
x  10-3). i, Interface between stacking gel and resolving gel; df,  dye 
front. 
observation of Solum et al. (23), demonstrating the existence 
of  complexes of  GPIb and a 240,000-260,000-mol-wt  protein. 
The identification of this protein as ABP is based upon the 
following facts:  (a) it is CBR-positive but PAS-negative and 
thus not likely a  glycoprotein (Fig.  2);  (b) it is not surface- 
labeled with  125I by the  lactoperoxidase method (Fig.  2)  or 
with  3H  by periodate oxidation and reduction with sodium 
borotritide3;  (c)  it  has  an  electrophoretic  mobility  in  SDS 
PAGE identical to that of ABP (Fig. 3); and, most important, 
(d)  it cross-reacts with antibodies specific for ABP (Fig.  3). 
Our data do not permit us to conclude that there is a direct 
linkage between GPIb and ABP, and the possibility that this 
association is mediated by additional platelet proteins remains 
to be investigated. In a  preliminary communication, Fox et 
al.  (6)  reported  that  GPIb  is  linked  to  a  250,000-mol-wt 
polypeptide in platelet cytoskeletons, but the protein in ques- 
tion was not identified.  In view of our findings, it is likely 
that the association described by Fox et al. (6) is identical to 
the GPIb-ABP interaction reported herein. 
The finding of GPIb-ABP complexes in platelet lysates as 
T. J. Kunicki, unpublished observation. 
described in this report or of a linkage between tritiated GPIb 
and the Triton-insoluble cytoskeleton as described by Fox et 
at.  (6)  would  suggest that  a  transmembrane linkage  exists 
between GPIb and ABP in the intact platelet. The potential 
physiologic relevance of such  an  interaction  is compelling, 
and  one  can  imagine that  this  transmembrane interaction 
could limit the mobility of both components in nonactivated 
platelets until the linkage is destroyed by activation of CANP. 
However,  the  possibility  that  this  association  only  occurs 
subsequent to platelet disruption must be considered, and a 
more rigorous confirmation of this hypothesis would entail 
analyses of the association(s) of GPIb within inta~ platelets. 
Aside from its association with a  17,000-22,000-mol-wt mi- 
nor glycoprotein, known as GPIX or GPI7 (2, 4,  14), the use 
of immunoelectron microscopy (18) or chemical cross-linking 
reagents (5)  has not revealed any significant interaction be- 
tween GPIb and other platelet proteins. However, the failure 
to observe such interactions with the latter method (5) may 
be related  to  the  relative difficulty in  detecting GPIb with 
protein-specific stains or by surface-radioiodination of plate- 
lets. 
Given that  a  transmembrane linkage between GPIb and 
the cytoskeleton does exist in intact platelets, one might expect 
that  agents  that  would  perturb  this  interaction  could  also 
influence GPIb receptor function.  In this regard, Coller (3) 
has  recently  reported  that  tertiary  amine  local  anesthetics 
initially cause an increase in the rate of vWf-dependent plate- 
let aggregation, whereas prolonged exposure to these agents 
produces a  significant inhibition  of vWf-dependent platelet 
agglutination that is temporally correlated with proteolysis of 
GPIb. Since such local anesthetics are also known to rapidly 
induce reversible platelet-sphering and retraction of pseudo- 
podia in the absence of proteolysis (12), it is conceivable that 
the enhanced vWf-dependent aggregation observed by Coller 
(3) is due to an increased mobility of vWf receptors (GPIb) 
caused by disruption  of the  GPIb-cytoskeleton interaction. 
Prolonged exposure to these agents sufficient to cause prote- 
olysis of GPIb and/or ABP results in  irreversible inhibition 
of vWf-dependent agglutination (3) and irreversible platelet- 
sphering (12). Studies are now in progess to analyze in greater 
detail the effect of GPIb-ABP complex integrity upon platelet 
functions attributed to GPIb. 
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